{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.2","upperLimit":"93.3","value":"90.0"},{"groupId":"OG001","lowerLimit":"39.6","upperLimit":"52.4","value":"46.1"}]}],"title":"DFS rate at 2 years (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.8","upperLimit":"87.8","value":"83.5"},{"groupId":"OG001","lowerLimit":"27.8","upperLimit":"40.0","value":"33.8"}]}],"title":"DFS rate at 3 years (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.0","upperLimit":"62.1","value":"53.0"},{"groupId":"OG001","lowerLimit":"19.0","upperLimit":"31.2","value":"24.9"}]}],"title":"DFS rate at 5 years (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken once daily","id":"OG000","title":"AZD9291 80mg Tablet"},{"description":"Taken once daily","id":"OG001","title":"Placebo Tablet"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS) stage IIA-IIIA patients","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.","title":"Disease Free Survival (DFS) Rate at 2, 3 and 5 Years","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}